ABSTRACT
Introduction
To describe the changes in systemic treatments (ST) of synchronous metastatic hormone-sensitive
prostate cancer (mHSPC) patients in a “real-world” setting and to explore reasons
why contemporary standard of care (SOC) was not administrated to the patient.
Patients and methods
Since 2014, we prospectively register mHSPCpatients. Patients were grouped in 4 time
periods: group 1 (Time period 1, January 2014-July 2015), group 2 after introduction
of docetaxel (Time period 2, August 2015-July 2017), group 3 after introduction of
abiraterone acetate (Time period 3, August 2017-February 2018) and group 4 after introduction
of apalutamide (Time period 4, March 2018-October 2021). For every time period, we
evaluated the initiated additional ST. In case patients received treatment that differed
from contemporary SOC according to guidelines, reasons for this difference were explored.
Results
In total, 243 patients were included. A progressive decline in ADT monotherapy from
85% to 29% over time was observed. The proportion of patients receiving additional
STs increased from 34% to 59%. Fourty percent of patients were not treated according
to contemporary SOC, but this percentage varied strongly per time period (10%, 67%,
53% and 32% from time period 1 to time period 4 respectively). Reasons for these variations
were heterogenous and varied across the 4 time periods. Patients being unfit for treatment
and treating physicians failing to consider additional STs were the most prevalent
reasons. The proportion of patients unfit for additional ST decreased from 18% to
4% over time.
Conclusion
Use of ADT monotherapy declined gradually after the introduction of additional systemic
treatments. The proportion of patients unfit for additional ST declined as more treatments
became available. Although compliance to SOC increased over time, these real-world
data show that adherence to clinical practice guidelines remains suboptimal. Efforts
should be made by clinicians to increase the adherence to practice guidelines.
MICROABSTRACT
In the last decade, a shift has occurred in the treatment of patients with newly diagnosed
metastatic prostate cancer (ndMPC) from ADT monotherapy to early combination therapies
of ADT with docetaxel or ARTAs. Although the introduction of novel systemic therapies
has made more patients eligible for additional treatments, adherence to clinical practice
guidelines remains suboptimal.
Key words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Genitourinary CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
REFERENCES
- Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).Eur Urol. 2015 Jun; 67: 1028-1038
- Contemporary Role of Androgen Deprivation Therapy for Prostate Cancer.Eur Urol. 2012 Jan; 61: 11-25
- Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.Eur Urol. 2019 Jan; 75: 88-99
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.N Engl J Med. 2015 Aug 20; 373: 737-746
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.N Engl J Med. 2017 Jul 27; 377: 352-360
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.N Engl J Med. 2019 Jul 4; 381: 13-24
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.N Engl J Med. 2019; 381: 121-131
- ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC).J Clin Oncol. 2018 Feb 20; 36 (_suppl–TPS383): TPS383
- EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer.Update. 2020;
- IMAGINE—IMpact Assessment of Guidelines Implementation and Education: The Next Frontier for Harmonising Urological Practice Across Europe by Improving Adherence to Guidelines.Eur Urol. 2021 Feb; 79: 173-176
- Treatment patterns and survival in metastatic castration-sensitive prostate cancer in the US Veterans Health Administration.Cancer Med. 2021 Dec 2; 10: 8570-8580
- The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.Am J Surg Pathol. 2016 Feb; 40: 244-252
- Treatment of patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) in Belgium: a real world data analysis.Acta Clin Belg. 2021 Nov 18; : 1-9
- EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer.Eur Urol. 2014 Feb; 65: 467-479
- Abiraterone for prostate cancer not previously treated with hormone therapy.N Engl J Med. 2017; 377: 338-351
- ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.J Clin Oncol. 2019 Nov 10; 37: 2974-2986
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.Lancet. 2016; 387: 1163-1177
- Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I.J Urol. 2021 Jan; 205: 14-21
- EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer.Eur Urol. 2021 Feb; 79: 263-282
- NCCN Guidelines Insights: Prostate Cancer, Version 1.2021.J Natl Compr Cancer Netw. 2021 Feb; 19: 134-143
- Absolute Prostate-Specific Antigen Value After Androgen Deprivation Is a Strong Independent Predictor of Survival in New Metastatic Prostate Cancer: Data From Southwest Oncology Group Trial 9346 (INT-0162).J Clin Oncol. 2006 Aug 20; 24: 3984-3990
- A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1.J Clin Oncol. 2021 May 20; 39 (_suppl–5000): 5000
- Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.Lancet. 2018;
- Multicentre, prospective study on local treatment of metastatic prostate cancer (LoMP study).BJU Int. 2021 Jul 21; : bju.15553
- Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States.J Urol. 2021 Dec; 206: 1420-1429
- Treatment patterns in men with metastatic castration sensitive prostate cancer (mCSPC) in the United States (US).J Clin Oncol. 2020 May 20; 38 (_suppl–e19131): e19131
- Disease and Treatment Characteristics of Men Diagnosed With Metastatic Hormone-Sensitive Prostate Cancer in Real Life: Analysis From a Commercial Claims Database.Clin Genitourin Cancer. 2017 Apr; 15 (e1): 273-279
Article Info
Publication History
Accepted:
November 2,
2022
Received in revised form:
October 30,
2022
Received:
May 28,
2022
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2022 Published by Elsevier Inc.
